NB 1011

Drug Profile

NB 1011

Alternative Names: NB1011; Thymectacin

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator NewBiotics
  • Developer Kiadis Pharma
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 21 Sep 2015 Discontinued - Phase-I/II for Solid tumours in USA, Canada (IV) before September 2015
  • 18 Jul 2007 NB 1011 is still in phase I/II trials for Solid tumours in North America
  • 26 Jul 2004 NewBiotics has been acquired by Celmed BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top